Brain and heart-specific death in cancer patients: Population-based study

Mohammed Safi | Murad Al-Nusaif | Dario Trapani | Mubarak A Mashrah
Ravindran Kanesvaran | Aziz Alzandani | Mahmoud Al-Azab | Syed A Mazher
Abdullah Al-Danakh | Jiwei Liu

Abstract

Background: The occurrence of cardiovascular events is a major cause of death in patients with cancer. Small studies have documented a connection between specific brain alterations and autonomic cardiac dysfunctions, possibly resulting in a worse prognosis. We aimed to refine the knowledge of fatal cardiac events in patients with brain metastasis (BM).

Methods: We performed a Surveillance, Epidemiology, and End Results SEER registry-based investigation (timeline: 2010–2016) and extracted all the advanced patients who had experienced fatal cardiac outcomes. Populations were compared according to the presence or not BM. Kaplan–Meier (KM) methodology was used for survival analysis and a multivariate model was developed by adjusting for multiple possible confounders.

Results: Most related BM and cardiac death were observed at the site of lung cancer (81.4%). We extracted 3187 patients with lung cancer site, including 417 patients who had experienced fatal heart-specific with a history of BM, which is considered a BM group. The second group of heart-specific death included 2770 patients was stated as a non-BM group. Patients who had experienced heart-specific death in the BM group were predominately male, right side, upper site, and non-small type (62.11%, 54.92%, 51.56%, 69.78%), respectively. The survival outcomes between BM and the non-BM was significantly prominent ($p=0.003$; median: 2 months vs. 3 months). The negative prognostic independent significance of heart-fatal events was confirmed after adjusting for multiple variables ($HR=0.76$, CI = 0.68–0.84, $p < 0.0001$). The metastatic liver site was significantly associated with poorer survival rates ($HR=0.68$, CI = 0.52–0.88, $p = 0.005$). We revealed a possible connection between the brain and heart functions.

Conclusions: The prognosis of heart-specific death patients in BM is unfavorable compared to non-BM settings in lung cancer. We may be at the gates of a new field of neurocardiooncology.
1 | INTRODUCTION

An increasing body of evidence points to a functional connection between cerebral vascular injuries and damaged cardiac functions, which has been proposed as another cause of heart dysfunction in patients with neurological changes. Although data for the role of pre-existing cardiac conditions in raising the likelihood of ischemic stroke is being consolidated, evidence for cerebral ischemic events that can lead to abnormalities of heart function has been identified. However, there is no clear evidence of the perception of other brain disorders, including malignancies, causing cardiac changes.

Brain metastasis (BM) is crippling and potentially life-threatening diseases and commonly affects detrimentally patient’s prognosis and quality of life. BM is widespread in patients with lung cancer, accounting for up to 40% of cases in the advanced stage. The treatment of BM in lung cancer has had some effect on the outcome, whether with whole-brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), or SRS-accompanied surgical resection. Although significant advances have been made in cancer management in recent years, the prognosis for BM patients is still poor.

The therapeutic and preventative approaches for progressive atherosclerosis are now ready to be considered a popular underline of illness as a population finding in ischemic syndromes and clinical practice. The interconnection between heart and brain has been studied in several disease models of non-ischemic brain disorders, such as Alzheimer’s disease (AD), demonstrating the concept of non-atherosclerosis pathways of heart-brain interrelationship. As a result, we questioned if the presence of BM could impair particular autonomic central functions and affect cardiovascular morbidity and mortality, leading to patients’ poor prognosis in this setting. In order to answer this issue, we designed the first research in the field, which looked at the rate of fatal cardiac events in cancer patients with and without BM, as well as the associated survival.

2 | PATIENT AND METHODS

The ethical statement is given permission to the SEER study data files by using the reference number 19916-Nov2019. The SEER database details are not subject to informed patient consent. SEER 18 registries 2019 patients were marked with additional treatment fields using SEER* Stat software (version 8.3.8). The SEER program of the National Cancer Institute is responsible for the collection and reporting of cancer incidence and survival data from several populations on the basis of central cancer registries that cover approximately 30% of the U.S. population. The SEER data include patient demographic information, primary tumor site, tumor morphology, stage at diagnosis, first course of cancer treatment, and follow-up for vital status. First, collect all cancer sites (Site recode ICD-O-3/WHO 2008) with years interval (2010–2016) with stage IV Adult patients’ data were collected from the SEER public database based on the 2019 submission; the incidence data with additional treatment fields were included. The majority of associated BM and heart-specific death was seen in lung cancer site (81.4%) Supporting Information File 1. Then, we extracted data on patients with Stage IV Lung and bronchus (Site recode ICD-O-3/WHO 2008) with a period between 2010 and 2016 and divided the population into two groups: BM group and non-BM group.

Only patients with active follow-up during and after treatments were included to minimize the missing data. The following variables were selected: age (20 years or more), sex (male or female), tumors subtype (based on the ICD-O-3 convention from the International Classification of Diseases for Oncology—Third Edition, considering only invasive tumors), Histobehave (non-small type, small type, others), tumors grading (I–II, III–IV, unknown), race (Black, White, or others), primary site labelled (upper, lower, or others), metastatic sites (bone, liver, or lung), receipt of radiation treatment or chemotherapy treatment, laterality (right, left, or others), marital and insurance status. We used the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines to conduct the investigation.

The baseline demographics of patients were compared using the chi-squared test and t-test for categorical or continuous variables. We analyzed the survival curves with the KM method; the survival curves were compared with the log-rank test and Cox proportional hazard model for multivariate analysis. Significance was set at $p < 0.05$. Graphical abstract was provided to further explain pathways of brain-heart dysfunction interactions, according to the literature.

3 | RESULTS

We extracted 3187 patients with lung cancer from SEER (timeline: 2010–2016), including 417 patients who had experienced fatal heart-specific disease with a history of BM, which is considered as a BM group. The second group of heart-specific death included 2770 patients was stated as a non-BM group. Patients who had experienced heart-specific death in the BM group was predominately male,
right side, upper site, and non-small type (62.11%, 54.92%, 51.56%, 69.78%), respectively. Detailed other patients characteristics were summarized in Table 1.

The survival outcomes between BM and the non-BM was significant \( (p = 0.003; \text{median survival: 2 months vs. 3 months}) \). The negative prognostic independent significance of heart-fatal events was confirmed after adjusting for multiple variables (HR = 0.76, CI = 0.68–0.84, \( p < 0.0001 \)). Figure 1. The KM analysis showed a possible predictive value of multiple variables. However, we identified the drivers of the negative prognosis, mainly attributable to older (>74) male gender, white race with upper site location and left side in heart-specific patients with BM (<0.05). Besides the metastatic pattern to the lung, NSCLC type was negatively associated with poor survival in BM group \( (p = 0.0001, \text{Figure 2, Table 2}) \). The survival effect of each variable inside BM group is shown in Figure 3. In the study inside the BM group, the multivariate analysis confirmed that the metastatic liver site was significantly associated with poorer survival rates (HR = 0.68; CI = 0.52–0.88, \( p = 0.005 \)). Both treatment modality administration modalities (chemotherapy or radiation) were associated with improved survival based multivariate analyses in the BM group \( (HR = 1.27, CI = 1.03–1.56, p = 0.02; HR = 1.86, CI = 1.49–2.31, p < 0.0001) \) respectively Table 3.

### Discussion

The function of location and lateralization of brain lesions, clinical biomarkers, and manifestations of cardiac complications, and underlying mechanisms for brain-heart interaction were discussed in the literature.\(^9,10\) Neurocardiology has emerged as a discipline that deals with how the brain and the heart interact: the effects of heart damage on the brain and brain damage on the heart.\(^11,12\) Byer et al. stated for the first time that cerebral vascular damage could cause myocardial damage.\(^13\) The sub-speciality in cardiology is now called neurocardiology.\(^14\) As most cases were found to

| Parameters | BM (N = 417) | Non-BM (N = 2770) |
|------------|-------------|-----------------|
| Age        |             | 0.0001          |
| 20–64      | 149 (35.73) | 535 (19.31)     |
| 65–74      | 168 (40.29) | 845 (30.51)     |
| >74        | 100 (23.98) | 1390 (50.18)    |
| Sex        |             | 0.396           |
| Male       | 259 (62.11) | 1660 (59.93)    |
| Female     | 158 (37.89) | 1110 (40.07)    |
| Race       |             | 0.260           |
| White      | 318 (76.26) | 2179 (78.66)    |
| Black      | 65 (15.59)  | 422 (15.23)     |
| Others     | 34 (0.08)   | 169 (6.1)       |
| Marital status | | 0.193         |
| Yes        | 191 (45.8)  | 1175 (42.42)    |
| Others     | 226 (493.41)| 1595 (57.58)    |
| Grade      |             | 0.001           |
| I–II       | 35 (8.39)   | 307 (11.08)     |
| III–IV     | 119 (28.54) | 569 (20.54)     |
| Unknown    | 263 (63)    | 1894 (68.38)    |
| Origin     |             | 0.807           |
| Right      | 229 (54.92) | 1489 (53.93)    |
| Left       | 160 (38.37) | 1101 (39.88)    |
| Others     | 28 (0.07)   | 171 (6.19)      |
| Mets site  |             | 0.05            |
| Lung       |             | 0.05            |
| Yes        | 88 (21.1)   | 708 (25.6)      |
| No         | 329 (78.9)  | 2062 (74.4)     |
| Bone       |             | 0.000           |
| Yes        | 122 (29.3)  | 584 (21.1)      |
| No         | 295 (70.7)  | 2186 (78.9)     |
| Liver      |             | 0.370           |
| Yes        | 67 (16.1)   | 399 (14.4)      |
| No         | 350 (83.9)  | 2371 (85.6)     |
| Primary site labeled | | 0.250         |
| Upper      | 215 (51.56) | 1295 (46.75)    |
| Lower      | 90 (21.58)  | 662 (23.9)      |
| Others     | 112 (0.27)  | 813 (29.35)     |
| Histology  |             | 0.044           |
| Non-small cell lung cancer | | 0.044         |
| Small cell lung cancer | | 0.044         |
| Others     | 74 (0.18)   | 641 (23.14)     |
| Radiation status | | 0.000         |
| Yes        | 250 (59.95) | 695 (25.09)     |
| No         | 167 (40.05) | 2075 (74.91)    |
be related, this research aims to provide the first data on cancer populations and focuses on fatal cardiac events in lung cancer site in the BM setting and associated survival.

Since the SEER program covers 28% of the US population, our findings are quite general. This research will affect the paradigms of BM screening, the techniques of clinical trials and the counselling of specific groups of cancer patients. In our study, the most presented organ related to BM and fatal cardiac events was the lung cancer site which comprises more than 80% of all cancer registered in SEER database. Besides, explain a similar hypothesis of non-vascular effect on cardiac function. With different survival, the fatal cardiac events experienced a lower remarkable survival in BM history than non-BM patients. The ischemic brain injury may play a negative predictor of survival and lead to unfavorable survival with
heart-specific patients as a novel non-vascular cause. In one prospective clinical study, Yu et al. reported the heart variability rate is a prognostic predictor in BM patients.\textsuperscript{15} Such variability of rate was hypothesized to derive from autonomic impairments caused by the presence of BM, namely a non-ischemic mechanism.

The predominant type of histology was attributed mostly to non-small-cell lung cancer NSCLC, which has the worse survival in patients with BM. Several reports reported the guidelines and risk factors for NSCLC BM.\textsuperscript{16–19} but non-survival inferiority and associated cardiac dysfunction were explained. In the multivariate analysis, we found the metastatic liver pattern has been associated with poorer survival of heart-specific death in BM patients. While the radiation and chemotherapy were associated with better survival, the specific type of chemotherapy or radiation site for BM was not determined.

Our study must be taken into account in the context of the drawbacks. Next, we could classify the BM for early diagnosis of cancer. SEER does not provide details on the disease's recurrence, so we did not recognize patients who acquired BM after the initial diagnosis. For cancers that appear to be present at an early stage, this is a significant disadvantage of the database. Other studies have shown that BM continues to occur over time in existing patients with the metastatic disorder.\textsuperscript{20,21} Second, there is no information on the volume or size of metastases present in the brain. Third, screening is not used for specific histologies in lung cancer site. As a result, BM incidence ratio is likely to underestimate the true figure in non-screened populations. Fourth, the exact cause of cardiac death in each group of either BM or non-BM was not detected. Furthermore, we only investigated lung cancer to pursue some consistency in the findings and have a more homogeneous population; the

| TABLE 2 | KM curve difference comparing heart-specific death patients in the BM group and non-BM group |
|---------|------------------------------------------------------------------------------------------------|
| Parameters | BM median (months) | Non-BM median (months) | Log rank |
| Age | | | |
| 20–64 | 3 | 4 | 0.017 |
| 65–74 | 2 | 3 | 0.010 |
| >74 | 1 | 2 | 0.007 |
| Sex | | | |
| Male | 2 | 2 | 0.019 |
| Female | 2 | 3 | 0.067 |
| Race | | | |
| White | 2 | 3 | 0.010 |
| Black | 2 | 3 | 0.053 |
| Others | 2 | 2 | 0.945 |
| Marital status | | | |
| Yes | 2 | 3 | 0.009 |
| Others | 2 | 2 | 0.083 |
| Grade | | | |
| I–II | 2 | 6 | 0.001 |
| III–IV | 2 | 4 | 0.001 |
| Unknown | 2 | 2 | 0.683 |
| Origin | | | |
| Right | 2 | 2 | 0.072 |
| Left | 2 | 3 | 0.018 |
| Others | 0 | 1 | 0.481 |
| Mets site | | | |
| Lung | | | |
| Yes | 1 | 2 | 0.015 |
| No | 2 | 3 | 0.024 |
| Bone | | | |
| Yes | 2 | 2 | 0.914 |
| No | 2 | 3 | 0.003 |
| Liver | | | |
| Yes | 1 | 1 | 0.660 |
| No | 2 | 3 | 0.004 |
| Primary site labeled | | | |
| Upper | 2 | 3 | 0.001 |
| Lower | 3 | 3 | 0.559 |
| Others | 1 | 1 | 0.235 |
| Histology | | | |
| Non-small cell lung cancer | 2 | 4 | 0.0001 |
| Small cell lung cancer | 2 | 2 | 0.605 |
| Others | 1 | 1 | 0.918 |

(Continues)
inclusion of patients with small-cell tumors could jeopardize the findings, though representing a smaller proportion. Also, we explored the neurocardiology continuum through associations, which might be a good preliminary approach but no more than hypothesis-generating.

Our analysis provides new insights, amid these limitations, into the epidemiology of BM in the United States. Data relating to the incidence of BM, the relative proportion of patients with known BM among different types of cancer, and the prognosis of patients with BM and associated fatal heart events will continue to help shape the development of screening and recommendations for care. The direct and indirect interconnections between the heart and brain injury of any cause have led to the new concept of cardiocerebral syndrome.22,23

FIGURE 3 KM curve showing OS difference in heart-specific death patients of the BM group

5 | CONCLUSION

In cancer patients, the majority of heart-related deaths were associated with the cancer of the lung. BM was significantly associated with lower survival of patients with heart-specific death than non-BM. Liver metastatic lesions were negatively associated with poor survival in BM patients. While preliminary, our findings call for further study and confirmation to understand better the processes of cardiac dysfunction in the presence of BM. Eventually, where validated, our research paves the way for personalized therapies for patients, especially to prevent, diagnose, and manage cardiovascular outcomes in the presence of BM, regardless of the presence of cardiovascular comorbidities or risk factors. We may be at the gates of a new field of scientific research on neurocardio-oncology that requires further investigation of the effects of cardiac function with brain cancer lesions.

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTIONS
Mohammed Safi: conceptualization, data curation, Formal analysis, software, writing - original draft, Mohammed,
| Parameters        | BM          | p value | Multivariate HR (CI) | p value | Non-BM       | p value | Multivariate HR (CI) | p value |
|-------------------|-------------|---------|----------------------|---------|--------------|---------|----------------------|---------|
| Age               |             |         |                      |         |              |         |                      |         |
| 20–64 Reference   |             | 0.013   | 1.01 (0.81–1.27)     | 0.34    | Reference    | 0.000   | 1.02 (0.9–1.14)      | 0.66    |
| 65–74 1.05 (0.84–1.32) | 0.613       | 1.05 (0.94–1.17) | 0.31     | 1.05 (0.94–1.17) | 0.31     |
| >74 1.44 (1.11–1.86) | 0.005       | 1.29 (1.16–1.42) | 0.000    | 1.09 (0.91–1.2) | 0.08     |
| Sex               |             |         |                      |         |              |         |                      |         |
| Male vs. Female   | 0.962 (0.79–1.31) | 0.450   | 0.91 (0.85–0.99)     | 0.02    | 0.86 (0.79–0.93) | 0.000   |
| Race              |             |         |                      |         |              |         |                      |         |
| White             |             | 0.63    |                      |         |              | 0.505   |                      |         |
| Black             | 1.08 (0.76–1.54) | 0.65    | 1.104 (0.94–1.16)    | 0.36    | 1.06 (0.91–1.25) | 0.40    |
| Others            | 1.2 (0.79–1.83) | 0.37    |                      |         |              |         |                      |         |
| Marital status    |             |         |                      |         |              |         |                      |         |
| Yes vs. others    | 1.01 (0.83–1.23) | 0.87    | 0.93 (0.87–1.01)     | 0.096   |              |         |                      |         |
| Grade             |             |         |                      |         |              |         |                      |         |
| I–II Reference    |             | 0.97    |                      |         |              |         |                      |         |
| III–IV            | 0.97 (0.66–1.42) | 0.89    | 1.26 (1.1–1.45)      | 0.001   | 1.2 (1.09–1.4) | 0.002   |
| Unknown           | 0.96 (0.67–1.36) | 0.82    | 1.55 (1.37–1.75)     | 0.000   | 1.2 (1.06–1.38) | 0.004   |
| Origin            |             |         |                      |         |              |         |                      |         |
| Right Reference   |             | 0.75    |                      |         |              | 0.06    |                      | 0.02    |
| Left              | 0.97 (0.79–1.18) | 0.78    | 0.92 (0.85–0.99)     | 0.04    | 0.92 (0.85–1.00) | 0.06    |
| Others            | 1.13 (0.76–1.680) | 0.53    | 1.07 (0.91–25)       | 0.40    | 0.81 (0.68–0.97) | 0.02    |
| Mets site         |             |         |                      |         |              |         |                      |         |
| Lung              | 0.78 (0.62–99) | 0.054   | 0.93 (0.85–1.01)     | 0.116   |              |         |                      |         |
| Yes vs. No        |              |         |                      |         |              |         |                      |         |
| Bone              | 0.98 (0.79–1.22) | 0.90    | 0.83 (0.76–0.915)    | 0.000   | 0.7 (0.70–0.85) | 0.000   |
| Yes vs. No        |              |         |                      |         |              |         |                      |         |
| Liver             | 0.69 (0.53–90) | 0.007   | 0.68 (0.52–0.88)     | 0.005   | 0.64 (0.58–0.71) | 0.000   |
| Yes vs. No        |              |         |                      |         |              |         |                      |         |

(Continues)
| Parameters              | BM                                       | Non-BM                                   |
|------------------------|------------------------------------------|------------------------------------------|
|                        | Univariate HR (CI) | p value | Multivariate HR (CI) | p value | Univariate HR (CI) | p value | Multivariate HR (CI) | p value |
| Primary site labeled   |                           |         |                        |         |                           |         |                        |         |
| Upper                  | Reference                  | 0.05    |                          | 0.000   |                           |         |                        |         |
| Lower                  | 0.84 (0.66–1.08)          | 0.185   | 0.98 (0.89–1.07)        | 0.000   | 0.84 (0.66–1.08)          | 0.185   | 0.98 (0.89–1.07)        | 0.000   |
| Others                 | 1.18 (0.94–1.49)          | 0.144   | 1.27 (1.16–1.39)        | 0.000   | 1.27 (1.16–1.39)          | 0.000   | 1.27 (1.16–1.39)        | 0.000   |
| Histology              |                           |         |                        |         |                           |         |                        |         |
| Non-small cell lung cancer | Reference               | 0.39    |                          | 0.000   |                           |         |                        |         |
| Small cell lung cancer | 0.94 (0.70–1.27)          | 0.71    | 1.47 (1.15–1.45)        | 0.000   | 1.47 (1.15–1.45)          | 0.000   | 1.47 (1.15–1.45)        | 0.000   |
| Others                 | 1.17 (0.90–1.51)          | 0.22    | 1.47 (1.34–1.60)        | 0.000   | 1.47 (1.34–1.60)          | 0.000   | 1.47 (1.34–1.60)        | 0.000   |
| Radiation status       |                           |         |                        |         |                           |         |                        |         |
| Yes vs. no             | 1.54 (1.26–1.87)          | 0.000   | 1.27 (1.03–1.56)        | 0.02    | 1.77 (1.62–1.93)          | 0.000   | 1.77 (1.62–1.93)        | 0.000   |
| Surgery                |                           |         |                        |         |                           |         |                        |         |
| Yes vs. no             | 2.24 (1.18–4.26)          | 0.013   | 1.88 (0.98–3.6)         | 0.05    | 2.27 (1.8–2.77)           | 0.000   | 2.27 (1.8–2.77)         | 0.000   |
| Chemotherapy           |                           |         |                        |         |                           |         |                        |         |
| Yes vs. no             | 2.05 (1.67–2.51)          | 0.0000  | 1.86 (1.49–2.31)        | 0.000   | 1.77 (1.64–1.92)          | 0.000   | 1.77 (1.64–1.92)        | 0.000   |
| Insurance              |                           |         |                        |         |                           |         |                        |         |
| Yes vs. others         | 0.96 (0.77–1.19)          | 0.71    | 1.09 (1.001–1.20)       | 0.047   | 1.09 (1.001–1.20)         | 0.047   | 1.09 (1.001–1.20)       | 1.00    |
Murad, Dario, and Mubarak: writing - review & editing interpretation. Ravindran, Aziz, Mahmoud, Syed, and Abdullah: visualization, validation: Jiwei Liu: supervision and project administration.

ETHICAL APPROVAL
The ethical statement is given permission to the SEER study data files by using the reference number 19916-Nov2019.

INFORMED CONSENT
Not applicable.

DISCLOSURE
The abstract was accepted in European lung cancer congress ELCC 2021.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study were derived from the following resource available in the public domain [www.seer.cancer.gov].

ORCID
Mohammed Safi https://orcid.org/0000-0001-7928-2343

REFERENCES
1. Chen Z, Venkat P, Seyfried D, Chopp M, Yan T, Chen J. Brain–heart interaction: cardiac complications after stroke. Circ Res. 2017;121(4):451-468.

2. Bengel FM, Hermanns N, Thackeray JT. Radionuclide imaging of the molecular mechanisms linking heart and brain in ischemic syndromes. Circ Cardiovasc Imaging. 2020;13(8):e011303.

3. Levy A, Faire-Finn C, Hasan B, et al. Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. Eur J Cancer. 2018;93:37-46.

4. Yu X, Fan Y. Real-world data on prognostic factors for overall survival in EGFR-mutant non-small-cell lung cancer patients with brain metastases. J Cancer. 2019;10(15):3486-3493. https://doi.org/10.7150/jca.30292. PMID: 31293653; PMCID: PMC6603428.

5. Singh R, Lehrer EI, Ko S, et al. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: a systematic review and meta-analysis of multidisciplinary approaches. Radiother Oncol. 2020;144:165-179. https://doi.org/10.1016/j.radonc.2019.11.010. Epub 2019 Dec 5 PMID: 31812932.

6. Chen XR, Hou X, Dinglin XX, et al. Treatment patterns and survival outcomes of non-small cell lung cancer patients initially diagnosed with brain metastases in real-world clinical practice. Front Oncol. 2020;10:581729. https://doi.org/10.3389/fonc.2020.581729

7. Stefanidis KB, Askew CD, Greaves K, Summers MJ. The effect of non-stroke cardiovascular disease states on risk for cognitive decline and dementia: a systematic and meta-analytic review. Neuropsychol Rev. 2018;28(1):1-15.

8. Ghaferi AA, Schwartz TA, Pawlik TM. STROBE reporting guidelines for observational studies. JAMA Surg. 2021;156(6):577.

9. Mueller K, Thiel F, Beutner F, et al. Brain damage with heart failure: cardiac biomarker alterations and gray matter decline. Circ Res. 2020;126(6):750-764. https://doi.org/10.1161/CIRCRESAHA.119.315813

10. Frey A, Sell R, Homola GA et al. Cognitive deficits and related brain lesions in patients with chronic heart failure. JACC: Heart Fail. 2018;6(7):583-592.

11. Zou R, Shi W, Tao J, et al. Neurocardiology: cardiovascular changes and specific brain region infarcts. Biomed Res Int. 2017;2017:5646348. https://doi.org/10.1155/2017/5646348

12. Shivkumar K, Ajjola OA, Anand I, et al. Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. J Physiol. 2016;394:173-184. https://doi.org/10.1113/JP271870

13. Byer E, Ashman R, Toth LA. Electrocardiograms with large, upright T waves and long QT intervals. Am Heart J. 1947;33(6):796-806.

14. Samuels MA. The brain–heart connection. Circulation. 2007;116(1):77-84.

15. Wang YM, Wu HT, Huang EY, Kou YR, Hseu SS. Heart rate variability is associated with survival in patients with brain metastasis: a preliminary report. BioMed Res Int. 2013;2013:1-6.

16. Koo T, Kim IA. Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment. Radiat Oncol J. 2016;34(1):1.

17. An N, Jing W, Wang H, et al. Risk factors for brain metastases in patients with non-small-cell lung cancer. Cancer Med. 2018;7(12):6357-6364.

18. Page S, Milner-Watts C, Perna M, et al. Systemic treatment of brain metastases in non-small cell lung cancer. Eur J Cancer. 2020;132:187-198.

19. Hendriks LE, Henon C, Auclin E, et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol. 2019;14(7):1244-1254.

20. Costa DB, Shaw AT, Ou SHI, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881.

21. Ou SHI, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661-668.

22. Doehner W, Ural D, Haeusler KG. Heart and brain interaction: cardiac complications after stroke. Eur J Heart Fail. 2018;20(2):199-215.

23. Havakuk O, King KS, Grazette L, et al. Heart failure-induced brain lesions in patients with chronic heart failure. J Am Coll Cardiol. 2017;69(12):1609-1616.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Safi M, Nusaif MA, Trapani D, et al. Brain and heart-specific death in cancer patients: Population-based study. Cancer Med. 2021;10:5739–5747. https://doi.org/10.1002/cam4.4069